Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Subject Areas on Research
-
A case of scurvy associated with nilotinib.
-
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
-
A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.
-
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
-
A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
-
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
-
A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia.
-
ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
-
Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia.
-
Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation.
-
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens.
-
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
-
An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse.
-
Application of FISH to complex chromosomal rearrangements associated with chronic myelogenous leukemia.
-
Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.
-
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study.
-
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
-
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
-
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
-
Bcr-Abl variants: biological and clinical aspects.
-
Breath ethane generation during clinical total body irradiation as a marker of oxygen-free-radical-mediated lipid peroxidation: a case study.
-
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
-
Characterization of the DNase I hypersensitive site 3' of the human beta globin gene domain.
-
Chronic Myelogenous Leukemia, Version 1.2014.
-
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
-
Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.
-
Chronic granulocytic leukemia in a patient with sickle cell anemia.
-
Chronic myelogenous leukemia.
-
Chronic myelogenous leukemia.
-
Chronic myelogenous leukemia.
-
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
-
Cloning and characterization of the major promoter of the human protein kinase C beta gene. Regulation by phorbol esters.
-
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
-
Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
-
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
-
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
-
Effects of treatment regimens on post marrow transplant relapse.
-
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
-
Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
-
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
-
Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
-
Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.
-
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.
-
Graft-versus-host reactions: anti-leukemia effects of donor T cells.
-
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.
-
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
-
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
-
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
-
Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
-
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.
-
Interleukin-2 therapy for advanced chronic myeloid leukemia.
-
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
-
Leukemia cutis in a patient with chronic neutrophilic leukemia.
-
Levels of p53 protein increase with maturation in human hematopoietic cells.
-
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
-
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.
-
Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia.
-
Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
-
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
-
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
-
Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases.
-
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
-
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
-
Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.
-
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
-
Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
-
Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.
-
Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
-
Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases.
-
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
-
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
-
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
-
NCCN task force report: molecular markers in leukemias and lymphomas.
-
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.
-
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.
-
Optic chiasm, optic nerve, and retinal involvement secondary to varicella-zoster virus.
-
Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study.
-
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
-
Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors.
-
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.
-
Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
-
Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
-
Poor Oral Health Linked with Increased Risk of Infectious Complications in Adults with Leukemia.
-
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
-
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
-
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
-
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
-
Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
-
Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration.
-
Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia.
-
Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation.
-
Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
-
Rendering the leukemia cell susceptible to attack.
-
Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.
-
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
-
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
-
Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual.
-
Sequential development of polycythemia vera and chronic myelocytic leukemia in a patient following radiation exposure from nuclear weapons tests.
-
Simultaneous presence of major secondary chromosomal abnormalities in blast crisis of chronic myeloid leukemia.
-
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
-
T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
-
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
-
Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.
-
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors.
-
The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
-
The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.
-
The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
-
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
-
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
-
The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.
-
Total hip arthroplasty in very young bone marrow transplant patients.
-
Treatment choices in chronic myelogenous leukemia.
-
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
-
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.
-
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.
-
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.
-
β-Arrestin2 mediates the initiation and progression of myeloid leukemia.
-
Keywords of People